LONDON, England, May 23 [Category: BizPharmaceuticals] -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release:

* * *

Blenrep (belantamab mafodotin) combinations receive positive CHMP opinion in relapsed/refractory multiple myeloma

* Positive opinion supported by superior efficacy shown in two head-to-head phase III trials, including overall survival in DREAMM-7

* If approved, Blenrep combinations co . . .

Click here for more information about our products